Renal tubular disease in the era of combination antiretroviral therapy

AIDS

Volumn 29, Issue 14, 2015, Pages 1831-1836

  Hamzah, Lisa ^a   Booth, John W ^b   Jose, Sophie ^b   Mcadooc, Stephen P ^c   Kumar, Emil A ^c   O'donnelld, Patrick ^d   Hilton, Rachel ^d   Sabin, Caroline ^b   Williams, Deborah I ^a   Jones, Rachael ^c   Post, Frank A ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Atazanavir; Drug induced kidney injury; HIV; Interstitial; Renal tubular disease; Tenofovir

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; RITONAVIR; TENOFOVIR; ANTIRETROVIRUS AGENT;

ADULT; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; ARTICLE; BLACK PERSON; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; ETHNICITY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL SYSTEM PARAMETERS; TUBULAR ATROPHY; UNITED KINGDOM; ADVERSE EFFECTS; AIDS-ASSOCIATED NEPHROPATHY; BIOPSY; CHEMICALLY INDUCED; COMPLICATION; CYTOCHEMISTRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INCIDENCE; KIDNEY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AIDS-ASSOCIATED NEPHROPATHY; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOPSY; FEMALE; HISTOCYTOCHEMISTRY; HIV INFECTIONS; HUMANS; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; UNITED KINGDOM;

EID: 84988704605     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000736     Document Type: Article

References (44)

1. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: A systematic review and meta-Analysis. BMC Public Health 2012; 12:234.
2. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009; 75:428-434.
3. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009; 10:329-336.
4. Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, Scheel PJ, et al. Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 2008; 28:478-486.
5. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L, et al. Immunodeficiency and renal impairment are risk factors for HIV-Associated acute renal failure. AIDS 2010; 24:2239- 2244.
6. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21:1119-1127.
7. Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, et al. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS 2014; 28:187-199.
8. Yombi JC, Pozniak A, Boffito M, Jones R, Khoo S, Levy J, et al. Antiretrovirals and the kidney in current clinical practice: Renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS 2014; 28:621-632.
9. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678.
10. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis 2013; 207:1359- 1369.
11. Perazella MA. Tenofovir-induced kidney disease: An acquired renal tubular mitochondriopathy. Kidney Int 2010; 78:1060- 1063.
12. Parkhie SM, Fine DM, Lucas GM, Atta MG. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 2010; 5:798-804.
13. Zaidan M, Lescure FX, Brocheriou I, Dettwiler S, Guiard- Schmid JB, Pacanowski J, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: A clinicopathological study. Clin J Am Soc Nephrol 2013; 8:930-938.
14. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78:1171-1177.
15. Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch 2007; 450:665-670.
16. Dunnill MS. A review of the pathology and pathogenesis of acute renal failure due to acute tubular necrosis. J Clin Pathol 1974; 27:2-13.
17. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int 1989; 35:1257-1270.
18. Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2007; 2:222-230.
19. Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001; 16:1163-1169.
20. The creation of a large UK-based multicentre cohort of HIV infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5:115-124.
21. Booth JW, McAdoo SP, Kumar EA, Turner-Stokes T, Das P, Naftalin C, et al. Spectrum of HIV-Associated kidney disease in the era of combination antiretroviral therapy. Presented at Kidney Week - American Society of Nephrology. Atlanta, GA; 2013.
22. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
23. Morelle J, Labriola L, Lambert M, Cosyns JP, Jouret F, Jadoul M. Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: A case of drug-drug interaction. Clin Nephrol 2009; 71:567-570.
24. Atta MG, Stokes MB. ASN clinical pathological conference. Tenofovir-related ATN (severe). Clin J Am Soc Nephrol 2013; 8:882-890.
25. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83:265-272.
26. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-Associated renal and bone toxicity. HIV Med 2009; 10:482-487.
27. Gupta SK. Tenofovir-Associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22:99-103.
28. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-Associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
29. Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, et al. Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study. Scand J Infect Dis 2012; 44:689-696.
30. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-273.
31. Kanzaki G, Tsuboi N, Miyazaki Y, Yokoo T, Utsunomiya Y, Hosoya T. Diffuse tubulointerstitial nephritis accompanied by renal crystal formation in an HIV-infected patient undergoing highly active antiretroviral therapy. Intern Med 2012; 51:1543-1548.
32. Nishijima T, Yazaki H, Hinoshita F, Tasato D, Hoshimoto K, Teruya K, et al. Drug-induced acute interstitial nephritis mimicking acute tubular necrosis after initiation of tenofovircontaining antiretroviral therapy in patient with HIV-1 infection. Intern Med 2012; 51:2469-2471.
33. Jaradat M, Phillips C, Yum MN, Cushing H, Moe S. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 2000; 35:E16.
34. Martinez F, Mommeja-Marin H, Estepa-Maurice L, Beaufils H, Bochet M, Daudon M, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998; 13:750-753.
35. Izzedine H, M'Rad MB, Bardier A, Daudon M, Salmon D. Atazanavir crystal nephropathy. AIDS 2007; 21:2357-2358.
36. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44:e81-e84.
37. Viglietti D, Verine J, De Castro N, Scemla A, Daudon M, Glotz D, et al. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir Ther 2011; 16:119-121.
38. Shafi T, Choi MJ, Racusen LC, Spacek LA, Berry C, Atta M, et al. Ritonavir-induced acute kidney injury: kidney biopsy findings and reviewof literature. Clin Nephrol 2011; 75 (Suppl 1):60-64.
39. Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, et al. High incidence of renal stones among HIV infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262-1269.
40. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir- boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:1671-1673.
41. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-Associated nephrolithiasis: Cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21:1215-1218.
42. Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis 2014; 210:363-373.
43. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55:78-81.
44. Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, et al. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Med 2014; 15:505-510.